Entity

Xenopat

Biotechnology - R&D Services

 

Xenopat is a company offering services based on the use of orthoxenografts®, mice in which a piece of human tumor is implanted in the same organ of origin. The tumor grows in the mouse mimicking the molecular features, drug response and metastatic dissemination pattern of the original human tumor. These models are extremely useful in order to develop new oncologic drugs, and also in personalized oncology treatment assessment strategies.

 

Xenopat has available more than 350 orthoxenograft models including long, colon, ovary, endometrial, pancreas, melanoma, head and neck, testicular and pediatric cases, among others.

 

These models are key tools for the new oncologic drug development in pre-clinical phases. Moreover, Xenopat has the know-how needed in order to generate new models in co-clinical stages.
Xenopat’s know how in the generation of orthoxenografts®, allows us to generate models from patients, testing in these models all the available therapeutic alternatives for the patient. Xenopat generates in real time a report informing about the most effective treatment for the patient according to his/her model and delivers it to the oncologist. Through this assessment, Xenopat finds the best therapy for each patient in every moment of his/her disease.

+34 934 039 354

anna.portela@xenopat.com

xenopat.com


Contact person: Anna Portela Mestres

Location: Ed. Hèlix - 02A03bis